Related Experiment Video

Updated: Aug 15, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology

J E Gerich1

  • 1Department of Medicine, Physiology and Pharmacology, University of Rochester School of Medicine, Rochester, NY 14642, USA. johngerich@compuserve.com

European Journal of Clinical Investigation
|May 25, 2002
PubMed

Insights

Conventional type 2 diabetes treatments fail to prevent disease progression. New strategies should focus on reversing insulin resistance and improving beta-cell function for better glycaemic control and disease management.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Research

Background:

  • Conventional type 2 diabetes treatments often fail to achieve adequate glycaemic control.
  • Progressive beta-cell dysfunction complicates long-term disease management.
  • Current approaches do not fully address the core pathogenetic mechanisms of type 2 diabetes.

Purpose of the Study:

  • To re-examine and redefine the clinical management of type 2 diabetes.
  • To incorporate new insights into underlying pathogenetic mechanisms.
  • To explore the potential of early, aggressive interventions targeting beta-cell dysfunction and insulin resistance.

Main Methods:

  • Review of current therapeutic regimens for type 2 diabetes.
  • Analysis of the roles of beta-cell dysfunction and insulin resistance.
  • Evaluation of emerging evidence on disease-modifying treatments.

Main Results:

  • Type 2 diabetes involves a complex interplay between beta-cell dysfunction and insulin resistance.
  • Treatments aimed at reversing insulin resistance and improving beta-cell function show promise.
  • Stepwise management strategies may not be sufficient to halt disease progression.

Conclusions:

  • Effective type 2 diabetes management requires addressing both insulin resistance and beta-cell dysfunction.
  • Early and aggressive interventions targeting these core mechanisms are crucial.
  • A paradigm shift in clinical management is needed to slow or prevent disease progression.

Related Concept Videos

Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.